Versant Ventures
Venture Capital
Active
San Francisco, United States
379
34M
181
15.16
57
0.52
90
- Stages of investment
- Areas of investment
Summary
In 1999 was created Versant Ventures, which is appeared as VC. The main office of represented VC is situated in the Menlo Park. The fund was located in North America if to be more exact in United States.
The current fund was established by Barbara Lubash, Brian Atwood, Donald B. Milder, Rebecca Robertson, Samuel Colella, William Link. Besides them, we counted 13 critical employees of this fund in our database.
Speaking about the real fund results, this VC is 5 percentage points more often commits exit comparing to other organizations. The average startup value when the investment from Versant Ventures is 50-100 millions dollars. The important activity for fund was in 2008. Despite it in 2019 the fund had an activity. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in 13-24 deals every year. This Versant Ventures works on 5 percentage points less the average amount of lead investments comparing to the other organizations. The top amount of exits for fund were in 2018.
The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Versant Ventures, startups are often financed by OrbiMed, Investor Growth Capital Limited, Frazier Healthcare Partners. The meaningful sponsors for the fund in investment in the same round are Pequot Capital, Novartis Venture Fund, Kleiner Perkins. In the next rounds fund is usually obtained by Kleiner Perkins, Novartis Venture Fund, Abingworth.
Among the most popular portfolio startups of the fund, we may highlight Audentes Therapeutics, Pharmion, Kythera Biopharmaceuticals. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. The fund has exact preference in some founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little. Among the most popular fund investment industries, there are Medical Device, Life Science.
Investor highlights
- Industry focus
- Geo focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Last fund
- Fund size
- USD 560000000
- Fund raised date
- 2021-04-21
Analytics
- Total investments
- 379
- Lead investments
- 57
- Exits
- 90
- Rounds per year
- 15.16
- Follow on index
- 0.52
- Investments by industry
- Health Care (267)
- Biotechnology (260)
- Medical (144)
- Medical Device (121)
- Therapeutics (94) Show 50 more
- Investments by region
-
- United States (333)
- Switzerland (25)
- Canada (6)
- Germany (2)
- Sweden (2) Show 5 more
- Peak activity year
- 2008
- Number of Unicorns
- 4
- Number of Decacorns
- 4
- Number of Minotaurs
- 3
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 14
- Avg. valuation at time of investment
- 113M
- Group Appearance index
- 0.94
- Avg. company exit year
- 9
- Avg. multiplicator
- 3.04
- Strategy success index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Abdera Therapeutics | 01 Jan 2022 | Biotechnology, Health Care, Health Diagnostics, Life Science | Early Stage Venture | British Columbia, Vancouver, Canada | |
Bright Peak Therapeutics | 11 Jun 2024 | Biotechnology, Therapeutics | Late Stage Venture | 90M | Switzerland, Basel-City, Basel |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.